KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.

Jianzhong Zhang, Yangfeng Ding, Ping Wang, Linfeng Li, Weili Pan, Yan Lu, Hao Cheng, Xian Jiang, Ji-Chen Ho, Shuping Guo, Seong Jun Seo, Linda Stein Gold, Andrew Blauvelt, Joe Zhuo, Yichen Zhong, Brandon Becker, Leona Liu, Subhashis Banerjee, Diamant Thaçi

J Dermatol 52(9) 1360-1367

PMID40671612
PMCIDPMC12411803
DOI10.1111/1346-8138.17834
发表日期2025-07-17
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。
摘要

摘要

POETYK PSO-3, a 52-week, double-blind, phase 3 study, evaluated the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in adult patients with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea. Secondary and additional endpoints included improvement on two patient-reported outcome measures: the Psoriasis Symptoms and Signs Diary (PSSD) total score and the Dermatology Life Quality Index (DLQI). Patients were randomized 1:2 to placebo or deucravacitinib 6 mg once daily; at week 16, patients receiving placebo crossed over to receive deucravacitinib. PSSD and DLQI score changes from baseline and response rates for achieving meaningful within-patient change from baseline in PSSD total score (≥ 15 points) and DLQI of 0 or 1 (DLQI 0/1) were assessed over 52 weeks. In POETYK PSO-3, 74 patients were randomized to placebo and 146 patients to deucravacitinib. At week 16, mean (95% confidence interval [CI]) PSSD total score changes from baseline were -1.9 (-6.9, 3.1) and -28.8 (-32.6, -25.0) in patients receiving placebo and deucravacitinib, respectively. At both weeks 16 and 52, the response rate for ≥ 15-point meaningful change in PSSD total score (95% CI) was 73.3% (65.3, 80.3) in the group randomized to deucravacitinib. At week 16, mean (95% CI) DLQI changes from baseline were -1.7 (-3.1, -0.4) and -7.4 (-8.4, -6.4) in patients receiving placebo and deucravacitinib, respectively. In patients randomized to deucravacitinib, DLQI 0/1 response rates (95% CI) at weeks 16 and 52 were 36.4% (28.5, 44.4) and 44.7% (36.5, 52.9), respectively. Deucravacitinib was associated with meaningful and sustained improvements in psoriasis symptoms and signs and in quality of life in Asian patients with moderate to severe plaque psoriasis. Trial Registration: ClinicalTrials.gov identifier: NCT04167462.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Change from baseline in PSSD total score over 52 weeks. At week 16, patients receiving placebo crossed over to receive deucravacitinib. CI, confidence interval; PSSD, Psoriasis Symptoms and Signs Diary.
非 KM Figure
FIGURE 2FIGURE 2 Response rates for ≥ 15‐point meaningful change from baseline in PSSD total score over 52 weeks. At week 16, patients receiving placebo crossed over to receive deucravacitinib. CI, confidence interval; PSSD, Psoriasis Symptoms and Signs Diary.
非 KM Figure
FIGURE 3FIGURE 3 Response rates for meaningful change in scores on PSSD individual items (≥ 2‐point improvement from baseline) at week 16 (A) and week 52 (B). At week 16, patients receiving placebo crossed over to receive deucravacitinib. CI, confidence interval; PSSD, Psoriasis Symptoms and Signs Diary.
非 KM Figure
FIGURE 4FIGURE 4 Change from baseline in DLQI over 52 weeks. At week 16, patients receiving placebo crossed over to receive deucravacitinib. CI, confidence interval; DLQI, Dermatology Life Quality Index.
非 KM Figure
FIGURE 5FIGURE 5 Response rates for DLQI 0/1 over 52 weeks. At week 16, patients receiving placebo crossed over to receive deucravacitinib. CI, confidence interval; DLQI 0/1, Dermatology Life Quality Index of 0 or 1.
非 KM Figure